Avidity Partners Management LP trimmed its holdings in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) by 83.2% in the fourth quarter, HoldingsChannel reports. The firm owned 11,800 shares of the medical research company’s stock after selling 58,600 shares during the period. Natera makes up 0.8% of Avidity Partners Management LP’s portfolio, making the stock its 29th biggest position. Avidity Partners Management LP’s holdings in Natera were worth $2,703,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of NTRA. Palladiem LLC acquired a new stake in Natera during the 4th quarter valued at $31,000. Horizon Investments LLC acquired a new stake in Natera during the 3rd quarter valued at $32,000. Bank of Jackson Hole Trust increased its holdings in Natera by 103.8% during the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 83 shares in the last quarter. Flagship Harbor Advisors LLC acquired a new stake in Natera during the 4th quarter valued at $41,000. Finally, Greenline Wealth Management LLC acquired a new stake in Natera during the 4th quarter valued at $41,000. 99.90% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In other news, Director Roelof Botha sold 78,000 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $220.31, for a total value of $17,184,180.00. Following the transaction, the director directly owned 1,076,198 shares in the company, valued at $237,097,181.38. This trade represents a 6.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Solomon Moshkevich sold 3,000 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $218.43, for a total value of $655,290.00. Following the completion of the transaction, the insider owned 137,643 shares in the company, valued at $30,065,360.49. This represents a 2.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 159,378 shares of company stock worth $34,640,860. 5.05% of the stock is currently owned by company insiders.
Natera Stock Performance
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on the company. Wells Fargo & Company raised their price target on Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a report on Friday, May 8th. JPMorgan Chase & Co. lifted their target price on Natera from $260.00 to $265.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Robert W. Baird set a $265.00 target price on Natera in a research note on Friday, May 8th. Morgan Stanley lowered their target price on Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a research note on Tuesday, March 3rd. Finally, Royal Bank Of Canada assumed coverage on Natera in a research note on Thursday. They issued an “outperform” rating and a $275.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and an average target price of $256.53.
View Our Latest Research Report on NTRA
About Natera
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Featured Articles
- Five stocks we like better than Natera
- Time to Sell? 3 Winners With Fading Technical Momentum
- Why These 2 Hotel Stocks Are Beating Travel Peers
- This Energy Stock Has Quietly Soared 130% in a Year
- 3 ‘Boring’ Dividend Stocks With Tasty Technical Setups
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
